6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT
Director Elections and Amended 2020 Stock Plan Approved at Clene Inc.
Material Contracts, Financial Results
Announces $7 Million Underwritten Offering of Common Stock
After Successful FDA Meeting, Filing Accelerated Approval NDA for ALS
Annual Report to Security Holders
Subaward Agreement with New York University Executed by Clene Inc.
Reports Full Year 2025 Financial Results And Recent Operating Highlights
Issues Stockholder Letter Highlighting Upcoming CNM-AU8® 2026 Catalysts
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Specialized Disclosure Report